^
7d
A Multikinase Inhibitor AX-0085 Blocks FGFR1 Activation to Overcomes Osimertinib Resistance in Non-Small Cell Lung Cancer. (PubMed, Biomedicines)
Additionally, AX-0085 inhibited AXL and FGFR1-dependent oncogenic events, including cell proliferation, clonogenicity, and migration. The dual inhibition of AXL and FGFR1 by AX-0085 can overcome acquired osimertinib resistance, supporting its potential as a therapeutic strategy for treating patients with osimertinib-resistant tumors.
Journal
|
EGFR (Epidermal growth factor receptor) • FGFR1 (Fibroblast growth factor receptor 1)
|
EGFR mutation
|
Tagrisso (osimertinib) • AX-0085 • simmitinib (SYHA1817)
11ms
AXL kinase inhibitor exhibits antitumor activity by inducing apoptotic cell death in triple-negative breast cancer cells. (PubMed, Biochim Biophys Acta Mol Cell Res)
Treatment of AX-0085 on in vivo mouse xenografts transplanted with 4 T1 cells showed a significant tumor reduction. Thus, our findings demonstrate that AX-0085 has an effective therapeutic role in TNBC by inhibiting AXL activation.
Journal
|
AXL (AXL Receptor Tyrosine Kinase) • CDK2 (Cyclin-dependent kinase 2) • GAS6 (Growth arrest specific 6)
|
AX-0085
almost3years
Antitumor activity of AX-0085, a novel AXL kinase inhibitor: Analysis of apoptotic cell death in triple-negative breast cancer cells. (ASCO 2023)
Our results demonstrated that AX-0085 selectively blocks AXL activation which confers an effective therapeutic value in the treatment of TNBC. Currently, AX-0085 is undergoing non-clinical trials.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BCL2 (B-cell CLL/lymphoma 2) • AXL (AXL Receptor Tyrosine Kinase) • CDK2 (Cyclin-dependent kinase 2) • CASP9 (Caspase 9)
|
PD-L1 expression • HER-2 expression • PGR expression • CDK2 expression
|
Cabometyx (cabozantinib tablet) • AX-0085